newsfilter
← Latest News
GlobeNewswire·

Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates

TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (OTCQB:MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation